Tram is a multicultural, international growth-minded independent C-suite Executive, and a certified Independent Non-Executive Director.

She has been a repeat tech company founder.

Today, she helps investors, boards and CEOs of B2B small caps expand their geographic and services footprint, and extract the optimal value from their technology and human capital assets before maximizing exit opportunities in the health, agrifood and impact sectors.

28+ years of operating leadership across North America, Europe and Asia in data-driven, service-oriented health, medical device, diagnostics,

e-commerce & direct-to-consumer wellness platforms and SaaS/AI sectors. She has served in executive, advisory, and fiduciary board positions at large public Fortune 50, private mid and small caps, Private Equity Venture Capital-backed, or founder-owned companies where she is praised for transitioning organizations into complex fast-paced markets and changing environments.

 

Tram is known for her relentless appetite to build and nurture relationships across disciplines and geographies, to bring the highest mutual value to each relationship, which resulted in long-term trusted cross-border partnerships.

Educated in Western and Anglo-Saxon environments, she is a lifelong learner capable of stepping out of her comfort zone. She is known for her team player's and market insights lenses while keeping a finger on financial, legal and operating risks, which makes a difference in the boardroom.

She is passionate about inclusion and giving back to the next generations. She serves the Global Center for Risk and Innovation as a member of its Europe Industry Leadership Board to mitigate global risks, Asterion Ventures impact fund as a Venture Partner Ecosystems and the IBA International Bar Association Environment, Health and Safety's Committee as Health & Safety Officer.
As an inclusive leader, she has been interviewed and featured in four chapters of “The 5 Disciplines of Inclusive Leaders: Unleashing the Power of All of Us” a book released by Korn Ferry in 2020. As a mentor, she has received an average rating of 9+ out of 10 by Endeavor Global scale-up CEOs.

 

A decade ago, she founded Vitanlink, a private holding co-founding, co-investing, providing advisory and fiduciary board services, and fractional C-level executive support for B2B(2C) SaaS AI-powered scale-ups from agri-food, health and wellness, MedTech, Digital Health, Private Equity and Venture Capital and single family office (GSNB).

 

PRIOR EXPERIENCE

 

Tram served as a board member with a co-founded AI-powered Fintech and later as the Executive Vice President of Ecosystems during the acquisition transition period.

She led the recruitment of a new CEO, the pivot of the company business model from a B2B to a B2C and B2B2C strategy, and the company’s board decisions during the acquisition and transition process in 2021. She was instrumental in facilitating the company’s valuation outcome, multiplied by 3 from the date of the fintech incorporation and by 10 from the acquisition date. She served as an independent lead board director for another emerging growth AI in
 healthcare company where she helped the board connect to and acquire a Fortune 100-listed MedTech US Group’s offer within 4 months.

 

Tram added value as a member of the EMEA Executive Board of Welch Allyn, owned since 2021 by Baxter International Inc (NYSE: BAX). She transformed the primary care eHealth market, products, and channel models and led the preparation, acquisition, and transition of the French entity by a European distributor that paved the way for the later acquisitions of a $2B entity by a large Fortune 500 listed company.

She assumed increasing levels of Profit and Loss accountability, ultimately serving as a member of the Johnson & Johnson OCD EMEA management board and expanding its international profitability growth and footprint for the $3 Billion JNJ’s IVD division, which led to a later successful spin-off to a large investment firm. She was awarded twice the Johnson & Johnson standards of leadership achievement.
Tram began her career as an EY auditor in Vietnam and Cambodia before moving to J&J (NYSE: JNJ) Ortho-Clinic Diagnostics.

 

Tram holds an MBA from McGill University, an active US Certified Public Accountant license [CPA New Hampshire State Board of Accounting], a certification in Private Company and Private Equity Portfolio Governance from the PDA, and the Financial Times Non-Executive Director Diploma. In addition to her King's College London LL.M (Master of Laws) in International Financial and Commercial Law, which enhances her risk management and corporate ESG governance skills, she regularly attends board director training and continuing education with various organizations such as the PDA, NACD and the FT NED Diploma or the Female Board Pool Europe. She is fluent in French (her native language) and English, has a professional command of German, and speaks Vietnamese.